Q1 EPS Forecast for Allogene Therapeutics Lifted by Analyst

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – HC Wainwright upped their Q1 2025 earnings estimates for Allogene Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.29). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06.

ALLO has been the topic of a number of other research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Allogene Therapeutics Stock Performance

Shares of ALLO stock opened at $1.63 on Friday. The stock’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $2.29. Allogene Therapeutics has a twelve month low of $1.32 and a twelve month high of $4.63. The company has a market capitalization of $354.14 million, a price-to-earnings ratio of -1.04 and a beta of 1.02.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Cibc World Markets Corp bought a new position in shares of Allogene Therapeutics during the 4th quarter worth approximately $26,000. PAX Financial Group LLC acquired a new stake in shares of Allogene Therapeutics in the 4th quarter valued at $27,000. RPO LLC bought a new stake in shares of Allogene Therapeutics in the 4th quarter worth about $31,000. Caption Management LLC acquired a new stake in shares of Allogene Therapeutics during the 4th quarter worth about $32,000. Finally, Syon Capital LLC bought a new position in Allogene Therapeutics during the 4th quarter valued at about $39,000. 83.63% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO David D. Chang sold 46,668 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the transaction, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the sale, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,866 shares of company stock worth $194,461. 24.30% of the stock is currently owned by company insiders.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).